Overview

Study of DISC-0974 in Participants With Myelofibrosis and Anemia

Status:
Not yet recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
This phase 1b/2a open-label study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of DISC-0974 as well as categorize the effects on anemia response in subjects with myelofibrosis and anemia.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Disc Medicine, Inc